CO6500125A1 - Suministro de curcumina por derivacion - Google Patents

Suministro de curcumina por derivacion

Info

Publication number
CO6500125A1
CO6500125A1 CO11009141A CO11009141A CO6500125A1 CO 6500125 A1 CO6500125 A1 CO 6500125A1 CO 11009141 A CO11009141 A CO 11009141A CO 11009141 A CO11009141 A CO 11009141A CO 6500125 A1 CO6500125 A1 CO 6500125A1
Authority
CO
Colombia
Prior art keywords
patient
cerebrospinal fluid
curcumin
brain
lumen
Prior art date
Application number
CO11009141A
Other languages
English (en)
Inventor
Thomas M Dimauro
Alan J Dextradeur
Sean Lilienfeld
Ramakrishna Venugopalan
Original Assignee
Codman & Shurtleff
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Codman & Shurtleff filed Critical Codman & Shurtleff
Publication of CO6500125A1 publication Critical patent/CO6500125A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/906—Zingiberaceae (Ginger family)
    • A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
    • C07D279/14—1,4-Thiazines; Hydrogenated 1,4-thiazines condensed with carbocyclic rings or ring systems
    • C07D279/18—[b, e]-condensed with two six-membered rings
    • C07D279/22—[b, e]-condensed with two six-membered rings with carbon atoms directly attached to the ring nitrogen atom
    • C07D279/24—[b, e]-condensed with two six-membered rings with carbon atoms directly attached to the ring nitrogen atom with hydrocarbon radicals, substituted by amino radicals, attached to the ring nitrogen atom
    • C07D279/28—[b, e]-condensed with two six-membered rings with carbon atoms directly attached to the ring nitrogen atom with hydrocarbon radicals, substituted by amino radicals, attached to the ring nitrogen atom with other substituents attached to the ring system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Un método para reducir o prevenir un trastorno del cerebro humano relacionado con la presencia de una sustancia patógena en el líquido cefalorraquídeo seleccionando un ser humano para tratarlo como paciente y colocar un extremo proximal de un primer catéter, que tiene por lo menos un primer lumen, en un primer lugar subdural en el cerebro del paciente para establecer una comunicación abierta entre el primer lumen y el líquido cefalorraquídeo del paciente. Por un periodo de tiempo prolongado, se administra un agente de curcumina seleccionado de por lo menos uno, entre un híbrido de curcumina y un análogo de curcumina, al líquido cefalorraquídeo para que interactúe con la sustancia patógena para atenuar su efecto en el cerebro.
CO11009141A 2010-01-29 2011-01-27 Suministro de curcumina por derivacion CO6500125A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US12/696,588 US20100286585A1 (en) 2009-01-26 2010-01-29 Shunt Delivery of Curcumin

Publications (1)

Publication Number Publication Date
CO6500125A1 true CO6500125A1 (es) 2012-08-15

Family

ID=43920767

Family Applications (1)

Application Number Title Priority Date Filing Date
CO11009141A CO6500125A1 (es) 2010-01-29 2011-01-27 Suministro de curcumina por derivacion

Country Status (6)

Country Link
US (1) US20100286585A1 (es)
EP (1) EP2359820A1 (es)
JP (1) JP2011157357A (es)
AU (1) AU2011200287A1 (es)
CA (1) CA2730634A1 (es)
CO (1) CO6500125A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8383865B2 (en) 2007-04-17 2013-02-26 Codman & Shurtleff, Inc. Curcumin derivatives
JP2010524959A (ja) 2007-04-17 2010-07-22 コドマン・アンド・シャートレフ・インコーポレイテッド アルツハイマー病を処置するためのヘリウムガスボーラス中のクルクミンの鼻腔投与
US7985776B2 (en) 2008-06-27 2011-07-26 Codman & Shurtleff, Inc. Iontophoretic delivery of curcumin and curcumin analogs for the treatment of Alzheimer's Disease
US7723515B1 (en) 2009-01-26 2010-05-25 Codman & Shurtleff, Inc. Methylene blue—curcumin analog for the treatment of alzheimer's disease
US20130253266A1 (en) 2012-03-22 2013-09-26 Codman & Shurtleff, Inc. Fluid management catheter and methods of using same
CN103272299B (zh) * 2013-05-31 2018-09-21 李�根 脑内多点注射头皮下埋置导液囊
US20190151239A1 (en) * 2016-07-28 2019-05-23 Cerebral Therapeutics LLC Infusing drug solution directly into brain fluid
EP3490653A1 (en) * 2016-07-28 2019-06-05 Cerebral Therapeutics Implantable intraventricular sampling and infusion access device
CN110402285A (zh) * 2018-02-23 2019-11-01 再生生物医疗公司 用于将干细胞和药物滴注入人脑室系统的方法、装置和系统
WO2022020314A1 (en) * 2020-07-20 2022-01-27 Cerebral Therapeutics, Inc. Fluid catheter device for recording brain state

Family Cites Families (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2955898A (en) * 1957-04-29 1960-10-11 Union Carbide Corp Thiazine dyestuffs and process of dyeing fibrous material
US4208511A (en) * 1977-01-19 1980-06-17 Ethicon, Inc. Isomorphic copolyoxalates and sutures thereof
US4105034A (en) * 1977-06-10 1978-08-08 Ethicon, Inc. Poly(alkylene oxalate) absorbable coating for sutures
US4140678A (en) * 1977-06-13 1979-02-20 Ethicon, Inc. Synthetic absorbable surgical devices of poly(alkylene oxalates)
US4205399A (en) * 1977-06-13 1980-06-03 Ethicon, Inc. Synthetic absorbable surgical devices of poly(alkylene oxalates)
DK147640C (da) * 1982-06-11 1985-05-06 Dumex Ltd As Fremgangsmaade til fremstilling af nitroimidazol-derivater
US4529556A (en) * 1983-08-19 1985-07-16 The Dow Chemical Company Bis((aryl)vinyl)benzenes
EP0478842A1 (de) * 1990-10-05 1992-04-08 PALL BIOMEDIZIN GmbH Filter zur Filtration menschlicher Cerebronspinalflüssigkeit
US6096740A (en) * 1990-11-06 2000-08-01 Ramot University Authority For Applied Research And Industrial Development Ltd. Dexanabinol derivatives and their use as neuroprotective pharmaceutical compositions
DE4137540A1 (de) * 1991-11-14 1993-05-19 Steigerwald Arzneimittelwerk Verwendung von praeparaten der curcuma-pflanzen
US5334315A (en) * 1992-01-17 1994-08-02 Pall Corporation Priming system
US5622944A (en) * 1992-06-12 1997-04-22 Affymax Technologies N.V. Testosterone prodrugs for improved drug delivery
JPH069479A (ja) 1992-06-26 1994-01-18 Kyodo Kumiai Okinawa Pref Gov Kinousei Shokuhin Kaihatsu Center ウコンからクルクミンを抽出する方法
US5874271A (en) * 1992-08-21 1999-02-23 Takara Shuzo Co., Ltd. Human glycosyltransferase gene, compounds and method for inhibiting cancerous metastasis
US5340808A (en) * 1992-11-13 1994-08-23 Warner Lambert Company Fused pyridazinoquinazolone derivatives as neurotrophic agents
IL112205A0 (en) 1994-01-06 1995-03-15 Res Dev Foundation Curcumin, analogues of curcumin and novel uses thereof
US5618552A (en) * 1995-03-06 1997-04-08 Ethicon, Inc. Absorbable polyoxaesters
US5595751A (en) * 1995-03-06 1997-01-21 Ethicon, Inc. Absorbable polyoxaesters containing amines and/or amido groups
US5607687A (en) * 1995-03-06 1997-03-04 Ethicon, Inc. Polymer blends containing absorbable polyoxaesters
US5597579A (en) * 1995-03-06 1997-01-28 Ethicon, Inc. Blends of absorbable polyoxaamides
US5648088A (en) * 1995-03-06 1997-07-15 Ethicon, Inc. Blends of absorbable polyoxaesters containing amines and/or amide groups
US5859150A (en) * 1995-03-06 1999-01-12 Ethicon, Inc. Prepolymers of absorbable polyoxaesters
US5464929A (en) * 1995-03-06 1995-11-07 Ethicon, Inc. Absorbable polyoxaesters
US5679864A (en) * 1995-11-03 1997-10-21 Gene Print Inc. Process for the synthesis of curcumin-related compounds
US6689085B1 (en) * 1996-07-11 2004-02-10 Eunoe, Inc. Method and apparatus for treating adult-onset dementia of the Alzheimer's type
US5980480A (en) * 1996-07-11 1999-11-09 Cs Fluids, Inc. Method and apparatus for treating adult-onset dementia of the alzheimer's type
US5891924A (en) * 1996-09-26 1999-04-06 Research Development Foundation Curcumin (diferuloylmethane) inhibition of NFκB activation
US5980481A (en) * 1997-05-08 1999-11-09 Transvivo, Inc. Method and apparatus for continuous peritoneal cascade dialysis and hemofiltration (CPCD/H)
US6258859B1 (en) * 1997-06-10 2001-07-10 Rhodia, Inc. Viscoelastic surfactant fluids and related methods of use
JP4114992B2 (ja) 1998-02-24 2008-07-09 協和醗酵工業株式会社 テトラヒドロクルクミン類の製造方法
US20040127470A1 (en) * 1998-12-23 2004-07-01 Pharmacia Corporation Methods and compositions for the prevention or treatment of neoplasia comprising a Cox-2 inhibitor in combination with an epidermal growth factor receptor antagonist
JP2000236843A (ja) 1999-02-22 2000-09-05 Lion Corp クルクミン類の製造方法
US6187332B1 (en) * 1999-06-14 2001-02-13 Wisconsin Alumni Research Foundation Acidic buffered nasal spray
CA2393440A1 (en) * 1999-12-03 2001-06-07 Emory University Curcumin analogs with anti-tumor and anti-angiogenic properties
DE10019171A1 (de) * 2000-04-07 2001-10-18 Schering Ag Zusammensetzungen zur Verwendung als Penetrationsverstärker in transdermalen Formulierungen für hoch lipophile Wirkstoffe
DE10031955A1 (de) * 2000-06-30 2002-01-17 Deutsches Krebsforsch Curcumin-Derivate mit gegenüber Curcumin verbesserter Wasserlöslichkeit und diese enthaltende Arzneimittel
US7416559B2 (en) * 2000-10-27 2008-08-26 Poly-Med, Inc. Micromantled drug-eluting stent
WO2002083614A1 (en) * 2001-04-18 2002-10-24 Laila, Impex Novel polyhydroxy curcumins having antioxidant activity
GB0113121D0 (en) * 2001-05-30 2001-07-18 Univ Leeds Biologically active photosensitisers
US6979470B2 (en) * 2001-07-17 2005-12-27 Metaproteomics, Llc Curcuminoid compositions exhibiting synergistic inhibition of the expression and/or activity of cyclooxygenase-2
US20060224234A1 (en) * 2001-08-29 2006-10-05 Swaminathan Jayaraman Drug eluting structurally variable stent
JP4179494B2 (ja) * 2001-10-23 2008-11-12 株式会社カネカ ペルオキシソーム増殖剤応答性受容体リガンド剤
WO2003068049A2 (en) * 2002-02-13 2003-08-21 Kuchta, John Controlled cerebrospinal infusion and shunt system
US6790979B2 (en) * 2002-04-17 2004-09-14 University Of North Carolina At Chapel Hill Curcumin analogues and uses thereof
US20030199594A1 (en) * 2002-04-23 2003-10-23 Rasik Shah Helium propellant composition for use with aerosols
US6884783B2 (en) * 2002-05-03 2005-04-26 Unigen Pharmaceuticals, Inc. 7-Hydroxy chromones as potent antioxidants
US20050020945A1 (en) * 2002-07-02 2005-01-27 Tosaya Carol A. Acoustically-aided cerebrospinal-fluid manipulation for neurodegenerative disease therapy
US7060733B2 (en) * 2002-08-15 2006-06-13 The Regents Of The University Of California Methods for treating pancreatitis with curcumin compounds and inhibitors of reactive oxygen species
AU2003303198A1 (en) * 2002-12-19 2004-07-14 New York University Method for treating amyloid disease
US20050031651A1 (en) * 2002-12-24 2005-02-10 Francine Gervais Therapeutic formulations for the treatment of beta-amyloid related diseases
US6866856B2 (en) * 2002-12-31 2005-03-15 Avon Products, Inc. Compositions and delivery methods for the treatment of wrinkles, fine lines and hyperhidrosis
US7582068B2 (en) * 2003-02-18 2009-09-01 Medtronic, Inc. Occlusion resistant hydrocephalic shunt
US7968115B2 (en) * 2004-03-05 2011-06-28 Board Of Regents, The University Of Texas System Liposomal curcumin for treatment of cancer
US20040220242A1 (en) * 2003-05-02 2004-11-04 Leland Shapiro Inhibitors of serine protease activity, methods and compositions for treatment of nitric oxide induced clinical conditions
CA2536738A1 (en) * 2003-08-26 2005-03-10 Research Development Foundation Aerosol delivery of curcumin
US7205011B2 (en) * 2003-11-14 2007-04-17 Board Of Regents, Acting For And On Behalf Of, University Of Arizona Anti-inflammatory activity of a specific turmeric extract
AU2004293030A1 (en) * 2003-11-20 2005-06-09 Angiotech International Ag Electrical devices and anti-scarring agents
US20050208095A1 (en) * 2003-11-20 2005-09-22 Angiotech International Ag Polymer compositions and methods for their use
US8841326B2 (en) * 2004-02-12 2014-09-23 Stc.Unm Therapeutic curcumin derivatives
WO2005113069A2 (en) 2004-05-14 2005-12-01 Research Development Foundation Use of circumin and analogues as inhibitors of acc2
US20060020329A1 (en) * 2004-05-26 2006-01-26 Medtronic Vascular, Inc. Semi-directional drug delivering stents
US20060004317A1 (en) 2004-06-30 2006-01-05 Christophe Mauge Hydrocephalus shunt
US7514092B2 (en) * 2004-12-22 2009-04-07 Avon Products, Inc. Compositions and methods of their use for improving the condition and appearance of skin
US7618662B2 (en) * 2004-12-22 2009-11-17 Avon Products, Inc Use of natural plant extracts in cosmetic compositions
US7351745B2 (en) * 2004-12-22 2008-04-01 Avon Products, Inc Compositions and methods of their use for improving the condition and appearance of skin
US20080201786A1 (en) * 2005-01-27 2008-08-21 Zygogen, Llp Transgenic Zebrafish Models of Alzheimer's Disease
US20080213404A1 (en) * 2005-02-04 2008-09-04 Johnson Randall S Hif Modulating Compounds and Methods of Use Thereof
ITFI20050031A1 (it) * 2005-02-21 2006-08-22 Stefan Coccoloni Una composizione farmaceutica atta a prevenire l'invecchiamento e l'insorgere di malattie vascolari,neoplastiche,cutanee e dell'apparato pilifero
MX2007012989A (es) * 2005-04-22 2008-01-11 Genentech Inc Metodo para tratar la demencia o la enfermedad de alheimer.
US20060264423A1 (en) * 2005-05-20 2006-11-23 Bioenvision, Inc. Methylene Blue Therapy of Viral Disease
CA2618404A1 (en) * 2005-08-04 2007-02-15 Angiotech International Ag Block copolymer compositions and uses thereof
US20070116757A1 (en) * 2005-11-08 2007-05-24 Collegium Pharmaceutical, Inc. Methylene Blue Derivatives
US9446226B2 (en) * 2005-12-07 2016-09-20 Ramot At Tel-Aviv University Ltd. Drug-delivering composite structures
WO2007070983A1 (en) * 2005-12-22 2007-06-28 Apollo Life Sciences Limited Transdermal delivery of pharmaceutical agents
US20080082036A1 (en) * 2006-04-25 2008-04-03 Medtronic, Inc. Cerebrospinal fluid shunt having long term anti-occlusion agent delivery
US20080090897A1 (en) * 2006-08-11 2008-04-17 The Johns Hopkins University Compositions and methods for neuroprotectin
US20080051691A1 (en) * 2006-08-28 2008-02-28 Wyeth Implantable shunt or catheter enabling gradual delivery of therapeutic agents
US20080075671A1 (en) * 2006-09-22 2008-03-27 Di Mauro Thomas M Intranasally administering curcumin to the brain to treat alzheimer's disease
US20090087385A1 (en) * 2006-09-22 2009-04-02 Di Mauro Thomas M Intranasally administering curcumin in a bolus of helium gas to treat alzheimers disease
US7642062B2 (en) * 2006-12-29 2010-01-05 Avon Products Inc. Compositions and methods of their use for improving the condition and appearance of skin
WO2008087803A1 (ja) * 2007-01-16 2008-07-24 Hokkaido University 抗酸化成分を封入したイオントフォレーシス用リポソーム製剤
US8383865B2 (en) * 2007-04-17 2013-02-26 Codman & Shurtleff, Inc. Curcumin derivatives
US7887503B2 (en) * 2007-11-20 2011-02-15 Mark Geiger Method and apparatus for removing harmful proteins from a mammalian's ventricular cerebrospinal fluid
US7745670B2 (en) * 2008-06-27 2010-06-29 Codman & Shurtleff, Inc. Curcumin-Resveratrol hybrid molecule
US7985776B2 (en) * 2008-06-27 2011-07-26 Codman & Shurtleff, Inc. Iontophoretic delivery of curcumin and curcumin analogs for the treatment of Alzheimer's Disease
US7723515B1 (en) * 2009-01-26 2010-05-25 Codman & Shurtleff, Inc. Methylene blue—curcumin analog for the treatment of alzheimer's disease
US7909643B2 (en) * 2009-02-27 2011-03-22 Tyco Electronics Corporation Cassette for a cable interconnect system

Also Published As

Publication number Publication date
US20100286585A1 (en) 2010-11-11
EP2359820A1 (en) 2011-08-24
AU2011200287A1 (en) 2011-08-18
CA2730634A1 (en) 2011-07-29
JP2011157357A (ja) 2011-08-18

Similar Documents

Publication Publication Date Title
CO6500125A1 (es) Suministro de curcumina por derivacion
CL2017003457A1 (es) Metodos para tratar tumores solidos usando terapia de combinacion del inhibidor de nanoparticulas mtor.
CL2017003458A1 (es) Metodos para tratar malignidad hematoligica usando terapia de combinacion del inhibidor de nanoparticulas mtor.
BR112018012182A2 (pt) dispositivo para tratamento fotodinâmico
CL2012002037A1 (es) Uso de agonista doble del glucagon-glp-1 como agente inotropico en el tratamiento de la cardiopatía o la disfuncion cardiaca
NI201200181A (es) Métodos de terapia combinada para tratar enfermedades proliferativas
PH12014501997A1 (en) Esketamine for the treatment of treatment-refractory or treatment-resistant depression
DOP2012000155A (es) Terapia combinada para el tratamiento del cancer y ensayos de diagnostico relacionados
CL2016002971A1 (es) Combinación.
MX2014012247A (es) Bacterias probioticas.
PE20160949A1 (es) Cepa aislada de clonostachys rosea para uso como agente de control biologico
CL2015000699A1 (es) Métodos para tratamiento de cáncer.
GT201500011A (es) Ácidos 5-aminotetrahidroquinolin-2-carboxílicos novedosos y su uso
WO2013169864A3 (en) TETRAHYDRO[1,8]NAPHTHYRIDINE SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORƴ AND THE TREATMENT OF DISEASE
EP2381957A4 (en) THERAPEUTIC MODULATION OF VAGINAL EPITHELIUM LIMITING LUBRICATION
CR20110142S (es) Manguito quirúrgico
CL2015001700A1 (es) Tratamiento de trastornos del ritmo circadiano
MX2012000034A (es) Metodos para el tratamiento o la prevencion de la fatiga.
BR112017006113A2 (pt) combinações sinérgicas de auristatina
CL2015003343A1 (es) Composición farmacéutica que comprende un agente terapéutico modificado en base a hemoglobina, para el tratamiento para tratar el cáncer, e imágenes de diagnóstico.
WO2015138773A3 (en) Optic neuropathy treatment and reduction of steroid-induced oxidative stress with stabilized polyunsaturated substances
GB201204263D0 (en) Giloma treatment
CR20140473A (es) Compuestos de pirazol como inhibidores de sglt1
MA40535A (fr) Imagerie et thérapie d'une inflammation et d'une infection ciblant hsp90
CL2012002852A1 (es) Metodo de tratamiento de la enfermedad de alzheimer midiendo el indice de agrandamiento ventricular en el cerebro usando inmunoglobulina intravenosa como agente terapeutico.